TrialThe journal of prevention of Alzheimer's disease2021

Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.

S L Lowe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.